Invention Grant
- Patent Title: Mutant KRas inhibitors
-
Application No.: US15568931Application Date: 2016-04-25
-
Publication No.: US10421764B2Publication Date: 2019-09-24
- Inventor: Said M. Sebti , Yangmei Li , Richard A. Houghten
- Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
- Applicant Address: US FL Tampa US FL Port St. Lucie
- Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.,Torrey Pines Institute for Molecular Studies
- Current Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.,Torrey Pines Institute for Molecular Studies
- Current Assignee Address: US FL Tampa US FL Port St. Lucie
- Agency: Meunier Carlin & Curfman LLC
- International Application: PCT/US2016/029180 WO 20160425
- International Announcement: WO2016/172692 WO 20161027
- Main IPC: C07D221/16
- IPC: C07D221/16 ; C07D401/04 ; C07D401/14 ; C07D513/04 ; A61K31/429 ; A61P35/00
Abstract:
Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.
Public/Granted literature
- US20180118761A1 MUTANT KRAS INHIBITORS Public/Granted day:2018-05-03
Information query
